1.3 ATA vs 1.5 ATA hyperbaric chambers: does the extra pressure matter?

The honest core claim

The core claim of this guide is uncomfortable for a buying decision: the 1.3 versus 1.5 question cannot be answered with direct evidence, because the trial does not exist. What can be done is to reason from the nearest available evidence, and to be clear about which parts are measured and which parts are inference.

Two facts do the heavy lifting. First, the one place a mild-to-moderate pressure was tested rigorously with high-concentration oxygen, at a dose above what a home chamber reaches, it did not beat pressurized air. Second, in a randomized crossover that used 1.41 ATA, almost exactly the midpoint between 1.3 and 1.5, there was no added benefit over breathing normal air at 1.0 ATA.

What the two numbers actually mean

1.0 ATA is sea level. 1.3 ATA is about 4 psi above ambient, the classic soft-shell rating, and roughly equivalent to being about 10 feet underwater. 1.5 ATA is about 7.3 psi above ambient, and roughly 16 feet. The difference between the two is about 6 feet of water, and it is the entire basis of the upgrade pitch.

Both sit below the line the Undersea and Hyperbaric Medical Society uses when it describes mild hyperbaric oxygen as unproven, which is exposures below about 1.5 ATA. That is a wording boundary rather than a safety threshold, and crossing it by 0.0 ATA or landing on it does not convert a wellness chamber into clinical equipment. Clinical hyperbaric oxygen therapy is defined as a hard-sided chamber at no less than 2.0 ATA breathing physician-prescribed medical-grade oxygen.

What the research shows by pressure

Every study below was re-verified against the National Library of Medicine record on September 29, 2026. Pressure and oxygen figures are quoted as the published abstracts state them.

Note the pressure column. The two strongest entries sit at or above 1.41 ATA and both came back negative or null. The positive results sit at 1.3 to 1.4 ATA. The animal study is included only so the record is complete, and it is not human evidence.

The trial where more pressure did nothing

The single most load-bearing study for this question is a 2022 systematic review in children with cerebral palsy. It identified five randomized controlled trials, four of them rated high quality, with independent reviewers and no declared conflicts of interest. All of them used 100% oxygen at 1.5 to 1.75 ATA. That is a genuinely higher dose than a home chamber reaches, and at a higher oxygen concentration than filtered room air.

The conclusion was not ambiguous. There is high-level evidence that hyperbaric oxygen therapy is ineffective for improving motor and cognitive function in these children, and moderate-level evidence that it produces more adverse events than pressurized air. In three of the five trials, the control group breathed pressurized air at the same pressure, and it improved about as much as the oxygen group did. The most common adverse event was middle ear barotrauma, reported in up to half the children.

If more pressure produced more effect, this is where it should have shown up. It did not. That is the empirical reason to be skeptical of a marketing pitch built entirely on a higher pressure number, and it is why this guide does not treat 1.5 ATA as an upgrade.

One honest caveat: a separate 2022 meta-analysis on the same condition reached the opposite conclusion. Its own certainty rating was very low, and it is included here so you can see the disagreement rather than only the conclusion this guide finds stronger.

The sham-arm problem nobody mentions

Here is the detail that makes the whole literature harder to read than it looks. In several of the mild-pressure studies, the control group was not sitting at normal pressure doing nothing. In the cerebral palsy review, the control was pressurized air at the treatment pressure. When pressurized air performs about as well as oxygen, you cannot tell whether any observed benefit came from the pressure, from the oxygen, or from the expectation of lying in a chamber.

This cuts in an unexpected direction. It is not only an argument against the higher number. It is also a caution against reading the positive 1.3 ATA results as proven oxygen effects. Several of the encouraging small studies compared a chamber session against passive recovery, which is a much weaker comparison than another chamber session.

The practical consequence for a buyer is this. The field cannot currently separate pressure from oxygen from expectancy. A spec-sheet upgrade from 1.3 to 1.5 ATA changes only one of those three variables, and it changes the one that the best available evidence suggests may not be doing much on its own.

What to compare instead of the number

If the pressure delta has nothing behind it, the money is better spent on the things that decide whether the device gets used and how long it lasts.

Pressure ratings on soft-shell listings are usually quoted without stating the pump, altitude, and temperature they were measured at. Ask for those conditions in writing.

Claims that do not hold up

Verdict

If you are choosing between a 1.3 ATA and a 1.5 ATA mild chamber, the pressure difference should not decide it. There is no trial comparing them, and the nearest rigorous evidence at a higher pressure with more oxygen found no advantage over pressurized air. Every positive mild-pressure result in the literature sits at 1.3 to 1.4 ATA.

Choose on construction, valves and pump, chamber volume, warranty, and service. If two chambers are otherwise equal and the 1.5 ATA model costs meaningfully more, the honest reading of the evidence is that you are paying for a number.

If a clinician has prescribed clinical hyperbaric oxygen therapy for a cleared indication, neither number is what you need. That protocol is a hard-sided chamber at 2.0 ATA or above with physician-prescribed medical-grade oxygen, delivered with trained staff and monitoring. The guide linked below covers that class decision in full.

And whichever you consider, note that the FDA's current communication about hyperbaric devices is a safety notice, and UHMS describes exposures below about 1.5 ATA as unproven. Treat any home chamber as a wellness device, not as treatment.

Sources and methodology

We checked manufacturer specifications, public pricing, the FDA device and safety record, UHMS guidance, and the National Library of Medicine on September 29, 2026. Every study cited here was re-verified against its PubMed record on that date, and pressures, oxygen concentrations, and sample sizes are quoted as the published abstracts state them. We did not test these chambers and do not claim personal treatment results. No head-to-head trial of 1.3 ATA against 1.5 ATA exists, so the comparison in this guide is reasoned from the nearest available evidence rather than measured directly. That limitation is stated in the article, not hidden in a footnote.

• Laureau 2022, hyperbaric oxygen in cerebral palsy for the high-level no-benefit finding at 1.5 to 1.75 ATA with 100% oxygen, the pressurized-air control finding, and the adverse-event rate.
• Nakao 2026, cognitive throughput at 1.41 ATA for the null result at the midpoint between 1.3 and 1.5 ATA.
• Nisa 2023, immune markers at 1.4 ATA for the natural killer cell finding and the absence of oxidative stress.
• Takemura 2022, mood at 1.3 ATA with 31% oxygen for the post-exercise mood outcome.
• Fu 2026, recovery signals at 1.3 ATA for the EEG, muscle signal, and lactate recovery measures.
• Mihailovic 2023, subsequent performance at 1.3 ATA for the cycling power and heart rate variability finding.
• Park 2018, low-pressure hyperbaric recovery for the lactate and heart rate recovery finding.
• Lin 2026, sleep quality at high altitude for the altitude-specific sleep outcome, which does not transfer to sea level.
• Efrati 2015 and Boussi-Gross 2024 for the 2.0 ATA fibromyalgia findings. Both carry conflict-of-interest flags.
• Izquierdo-Alventosa 2024 and 2020 for low-pressure fibromyalgia outcomes.
• Leys 2026 and Liberty 2026 for the chronic pain and fibromyalgia systematic reviews, including the limited-evidence framing.
• Zhang 2022, the opposing cerebral palsy meta-analysis included so the disagreement in the literature is visible.
• Nagatomo 2018, diabetic rats listed only to keep the record complete. It is animal evidence and not transferable to humans.
• UHMS indications and clinical HBOT definition for the hard-sided 2.0 ATA or above definition and the unproven status of mild hyperbaric oxygen below about 1.5 ATA.
• FDA letter to health care providers, August 25, 2025 for the current safety position on hyperbaric devices, including the injury and fire reports and the 510(k) product code CBF reference.
• FDA consumer fact sheet, archived 2023 for the cleared-use and unproven-claims language. The live URL for this page no longer resolves, so the archived copy is linked.
• openFDA 510(k) query, product code CBF for the device classification and clearance count, queried September 29, 2026.

This guide is an evidence explainer, not medical advice. Talk to a hyperbaric physician before buying or using any chamber. Human medical use requires a prescription.

Frequently asked questions